
The New Rules of Diagnostics: Lean Teams, Faster Revenue, Smarter Growth - MJ Hymes, i5 BioPartners
In this episode of Diagnosing Dx, I’m joined by MJ Hymes, Managing Partner at i5 BioPartners. MJ shares his journey from molecular biology into the commercial side of life sciences, and explains why great science alone is rarely enough to build a successful diagnostics or biotech company. We explore the gap between innovation and execution, why so many early-stage companies struggle to turn promising technology into real traction, and how the funding landscape has shifted for founders building today. We also discuss what it takes to get a life sciences company market-ready, from building leaner models earlier on to navigating commercialization, fundraising, and strategic support at the right time. From AI and multiomics to emerging technologies in diagnostics and drug discovery, this is a practical conversation about turning early-stage science into a real business.
Publisher
Diagnosing Dx
Link
podcasters.spotify.com/pod/show/medtech-disruptors2/episodes/The-New-Rules-of-Diagnostics-Lean-Teams--Faster-Revenue--Smarter-Growth---MJ-Hymes--i5-BioPartners-e3i9tno
Published
April 22, 2026
Duration
41 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
Elevra Consulting
Diagnosing Dx
@diagnosingdx
#fasterrevenue #smartergrowth #i5biopartners #lifesciences
